- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Ferris on Significance of CheckMate-141 Trial for Head and Neck Cancer
June 7th 2016, 9:59pm
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).
Dr. Dickler on MONARCH 1 Results in HR+/HER2- Breast Cancer
June 7th 2016, 9:39pm
Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.
Impressive Upfront Palbociclib PFS Benefit Confirmed in ER+/HER2- Breast Cancer
June 7th 2016, 8:26pm
Adding the CDK 4/6 inhibitor palbociclib (Ibrance) to letrozole reduced the risk of disease progression by 42% compared with letrozole alone in patients with ER-positive, HER2-negative advanced or metastatic breast cancer.
Long-Term Data Deepen Dabrafenib/Trametinib Benefit in Melanoma
June 7th 2016, 8:41am
The combination of dabrafenib and trametinib continued to demonstrate impressive overall survival and progression-free survival findings for patients with BRAF-mutant metastatic melanoma in 3-year follow-up data from the phase III COMBI-d study.
Dr. Dummer on NEMO Trial for NRAS-Mutant Melanoma
June 7th 2016, 4:01am
Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses the results of the phase III NEMO trial, which compared the efficacy of binimetinib with dacarbazine in patients with NRAS-mutant metastatic melanoma.
Alectinib Could Represent First-Line Standard in ALK-Positive NSCLC
June 7th 2016, 3:47am
Alectinib improved progression-free survival by 66% compared with the current standard crizotinib as initial inhibitor therapy in patients with advanced or recurrent ALK-positive non–small cell lung cancer.
Long-Term Follow-up Sustains Frontline Nivolumab/Ipilimumab Benefit in Melanoma
June 7th 2016, 3:22am
At a minimum follow-up of 18 months, the combination of nivolumab and ipilimumab reduced the risk of disease progression by 58% compared with ipilimumab alone, and single-agent nivolumab lowered the risk of progression by 45% versus ipilimumab monotherapy in patients with advanced melanoma.
Dr. Reardon on Nivolumab/Ipilimumab in Glioblastoma
June 7th 2016, 3:20am
David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).
Binimetinib Shows Rare PFS Benefit in NRAS-Mutant Melanoma
June 7th 2016, 2:44am
The MEK inhibitor binimetinib reduced the risk of progression or death by 38% compared with dacarbazine in patients with NRAS-mutant metastatic melanoma.
PD-L1 Inhibitor Avelumab Active in Advanced Mesothelioma
June 7th 2016, 1:57am
Avelumab demonstrated clinical activity in patients with advanced or unresectable mesothelioma, with an overall response rate of 14.3%.
Nivolumab Improves OS, ORR in Phase III Head and Neck Cancer Study
June 7th 2016, 1:13am
Treatment with single-agent nivolumab improved overall survival and objective response rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.
Black Women Who Are BRCA Carriers Less Likely to Pursue Breast and Ovarian Cancer Risk Reduction
June 7th 2016, 12:15am
Young black women with breast cancer are much less likely to have BRCA testing or, if they carry a BRCA mutation, to undergo risk-reducing prophylactic mastectomy or salpingo-oophorectomy.
Despite Recommendations, Aggressive Cancer Treatment Still Common at End of Life
June 6th 2016, 11:56pm
An analysis of over 28,000 patients younger than 65 with incurable cancers found that approximately three-fourths of them received aggressive care within the last 30 days of life and one-third died in the hospital.
Web App Boosts Survival for Lung Cancer Patients
June 6th 2016, 11:46pm
Patients with lung cancer who participated in a web-based system for reporting and tracking their symptoms achieved dramatic gains in survival compared with individuals who were followed with typical protocols.
Cancer Drugs Less Affordable in Poorer Countries Despite Lower Prices
June 6th 2016, 10:26pm
Researchers who set out to understand the affordability of cancer drugs across the globe concluded that lower prices in some poorer countries don’t equate to better access.
Dabrafenib/Trametinib Combo Highly Effective in BRAF-Mutant NSCLC
June 6th 2016, 8:33pm
The combination of dabrafenib and trametinib was highly effective as a treatment for patients with BRAF V600E-mutant non–small cell lung cancer.
Nivolumab Delivers Durable Responses in Hodgkin Lymphoma
June 6th 2016, 7:35pm
Single-agent nivolumab induced responses in 66% of patients with classical Hodgkin lymphoma who had progressed following autologous stem cell transplant and brentuximab vedotin.
Nivolumab 5-Year OS Rate Passes 30% in Advanced RCC
June 6th 2016, 5:15am
About one third of patients with advanced renal cell carcinoma who were treated with single-agent nivolumab in the second-line setting or later were still alive at 4 and 5 years in long-term follow-up data from phase I and phase II clinical trials.
Atezolizumab Effective in First-Line Setting in Bladder Cancer
June 6th 2016, 3:29am
Patients with metastatic urothelial carcinoma who were ineligible for standard cisplatin-based chemotherapy achieved a 24% reduction in tumor size and had a median survival of 14.8 months after taking the immunotherapy agent atezolizumab (Tecentriq).
Bernard Fox on Significance of Immunoscore Validation Project
June 6th 2016, 3:21am
Bernard A. Fox, PhD, chief, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute at Providence Portland Medical Center, discusses the significance of the Immunoscore Validation Project.